Concerns about the design of clinical trials for spinal muscular atrophy

Research output: Contribution to journalArticle

Abstract

The distinctive clinical course of SMA, characterized by slowing of the rate of degeneration with the passage of time, presents a special challenge to therapeutic clinical trial planning. Much of the actual functional decline may represent either an inevitable consequence of growth or the result of various secondary complications of weakness, making the study of agents intended to improve the course by increasing the level of SMN protein that much more difficult. Studies intended to demonstrate a slowing of the rate of degeneration, modeled upon clinical trials for ALS, are problematic. In contrast, short-term trials designed to demonstrate improved strength have substantial design advantages, but depend upon the demonstration of salutary effects of increased SMN that are plausible but at present only theoretical. This form of study thus has some potential for type II error, falsely rejecting a useful drug. Despite this limitation, logistic and statistical concerns suggest that the best strategy for evaluating any promising new therapy will be to use first a short-term study.

Original languageEnglish (US)
Pages (from-to)456-460
Number of pages5
JournalNeuromuscular Disorders
Volume14
Issue number8-9
DOIs
StatePublished - Sep 2004

Fingerprint

Spinal Muscular Atrophy
Clinical Trials
Therapeutics
Growth
Pharmaceutical Preparations
Proteins

Keywords

  • Clinical trial design
  • SMN
  • Spinal muscular atrophy (SMA)

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Concerns about the design of clinical trials for spinal muscular atrophy. / Crawford, Thomas Owen.

In: Neuromuscular Disorders, Vol. 14, No. 8-9, 09.2004, p. 456-460.

Research output: Contribution to journalArticle

@article{0711f66e58274835b35e6083995dda57,
title = "Concerns about the design of clinical trials for spinal muscular atrophy",
abstract = "The distinctive clinical course of SMA, characterized by slowing of the rate of degeneration with the passage of time, presents a special challenge to therapeutic clinical trial planning. Much of the actual functional decline may represent either an inevitable consequence of growth or the result of various secondary complications of weakness, making the study of agents intended to improve the course by increasing the level of SMN protein that much more difficult. Studies intended to demonstrate a slowing of the rate of degeneration, modeled upon clinical trials for ALS, are problematic. In contrast, short-term trials designed to demonstrate improved strength have substantial design advantages, but depend upon the demonstration of salutary effects of increased SMN that are plausible but at present only theoretical. This form of study thus has some potential for type II error, falsely rejecting a useful drug. Despite this limitation, logistic and statistical concerns suggest that the best strategy for evaluating any promising new therapy will be to use first a short-term study.",
keywords = "Clinical trial design, SMN, Spinal muscular atrophy (SMA)",
author = "Crawford, {Thomas Owen}",
year = "2004",
month = "9",
doi = "10.1016/j.nmd.2004.04.004",
language = "English (US)",
volume = "14",
pages = "456--460",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Limited",
number = "8-9",

}

TY - JOUR

T1 - Concerns about the design of clinical trials for spinal muscular atrophy

AU - Crawford, Thomas Owen

PY - 2004/9

Y1 - 2004/9

N2 - The distinctive clinical course of SMA, characterized by slowing of the rate of degeneration with the passage of time, presents a special challenge to therapeutic clinical trial planning. Much of the actual functional decline may represent either an inevitable consequence of growth or the result of various secondary complications of weakness, making the study of agents intended to improve the course by increasing the level of SMN protein that much more difficult. Studies intended to demonstrate a slowing of the rate of degeneration, modeled upon clinical trials for ALS, are problematic. In contrast, short-term trials designed to demonstrate improved strength have substantial design advantages, but depend upon the demonstration of salutary effects of increased SMN that are plausible but at present only theoretical. This form of study thus has some potential for type II error, falsely rejecting a useful drug. Despite this limitation, logistic and statistical concerns suggest that the best strategy for evaluating any promising new therapy will be to use first a short-term study.

AB - The distinctive clinical course of SMA, characterized by slowing of the rate of degeneration with the passage of time, presents a special challenge to therapeutic clinical trial planning. Much of the actual functional decline may represent either an inevitable consequence of growth or the result of various secondary complications of weakness, making the study of agents intended to improve the course by increasing the level of SMN protein that much more difficult. Studies intended to demonstrate a slowing of the rate of degeneration, modeled upon clinical trials for ALS, are problematic. In contrast, short-term trials designed to demonstrate improved strength have substantial design advantages, but depend upon the demonstration of salutary effects of increased SMN that are plausible but at present only theoretical. This form of study thus has some potential for type II error, falsely rejecting a useful drug. Despite this limitation, logistic and statistical concerns suggest that the best strategy for evaluating any promising new therapy will be to use first a short-term study.

KW - Clinical trial design

KW - SMN

KW - Spinal muscular atrophy (SMA)

UR - http://www.scopus.com/inward/record.url?scp=4344647889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344647889&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2004.04.004

DO - 10.1016/j.nmd.2004.04.004

M3 - Article

C2 - 15336685

AN - SCOPUS:4344647889

VL - 14

SP - 456

EP - 460

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 8-9

ER -